Bone Biologics Corporation(BBLG)Earnings, Financials & Key Ratios

BBLG•NASDAQ

$1.35

Price updated Jun 27, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryOrthopedics, spine, and sports medicine

AboutBone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.Show more

Revenue$0
EBITDA-$3M-1931150.3%
Net Income-$3M+24.4%
EPS (Diluted)-2.65+45.1%
ROE-70.17%+45.5%

BBLG Price & Volume

Bone Biologics Corporation (BBLG) stock price & volume — 10-year historical chart

Loading chart...

Pre-Revenue Clinical Development Drives Persistent Capital Erosion

Investment Thesis • Updated 2026Q1

VerdictNegative: The company's reliance on external funding to cover operating losses

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Binary clinical trial failure

Key Thesis Takeaways

Bone Biologics remains a high-risk, pre-revenue entity entirely dependent on the successful regulatory advancement of its NELL-1 protein technology.
The company's financial profile is characterized by consistent quarterly operating losses, which reached $805.1K in 2026Q1, and a rapidly depleting cash runway that necessitates potential future dilutive financing.
Investors should monitor the firm's ability to reach commercial milestones, as the current $88.9 million accumulated deficit underscores the significant capital destruction inherent in its long-term R&D-focused business model.

Verdict Logic

which totaled $766.0K in 2026Q1, combined with a shrinking cash balance of $4.5 million, suggests a high probability of further shareholder dilution.

BBLG Growth Metrics

Bone Biologics Corporation (BBLG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM32.97%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM28.13%

Return on Capital

10 Years-98.67%

5 Years-98.67%

3 Years-139.35%

Last Year-73.01%

Peers Comparison

Key metrics vs top competitors for Bone Biologics Corporation (BBLG)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
BBLGBone Biologics CorporationCurrent	$1.35	$2.42M	-0.51	—	—	-70.17%	—
XTNTXtant Medical Holdings, Inc.	$0.42	$58.92M	14.00	14.21%	1.5%	3.68%	—
ATECAlphatec Holdings, Inc.	$9.30	$1.41B	-9.69	24.95%	-21.07%	-443.09%	—
GMEDGlobus Medical, Inc.	$86.25	$11.63B	22.00	16.65%	18.92%	13.04%	—
OFIXOrthofix Medical Inc.	$9.78	$395.32M	-4.29	2.85%	-7.27%	-13.44%	—
ANIKAnika Therapeutics, Inc.	$15.10	$202.35M	-19.87	-5.91%	-9.52%	-7.74%	—